Foscarnet decreases human immunodeficiency virus RNA

Journal of Infectious Diseases

Volumn 172, Issue 1, 1995, Pages 225-227

  Kaiser, Laurent ^a   Perrin, Luc ^a   Hirschel, Bernard ^a   Furrer, Hansjakob ^a   Overbeck, Jan Von ^a   Olmari, Maya ^a   Yerly, Sabine ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; DIDANOSINE; FOSCARNET; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; RNA ANALYSIS; VIREMIA; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS INFECTIONS; FLOW CYTOMETRY; FOSCARNET; HIV; HIV CORE PROTEIN P24; HUMANS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RNA, VIRAL; SURVIVAL RATE; TIME FACTORS;

EID: 0029057845     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/172.1.225     Document Type: Article

References (12)

1. Koshida R, Vrang L, Gilljam G, Harmenberg J, Oberg B, Wahren B. Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscamet. Antimicrob Agents Che-mother 1989;33:778-80.
2. Eriksson BF, Schinazi RF. Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscamet) against human immunodeficiency vims type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1989;33:663-9.
3. Reddy MM, Grieco MH, McKinley GF, et al. Effect of foscamet therapy on human immunodeficiency vims p24 antigen levels in AIDS patients with cytomegalovirus retinitis. J Infect Dis 1992;166:607-10.
4. Fletcher CV, Collier AC, Rhame FS, et al. Foscamet for suppression of human immunodeficiency vims replication. Antimicrob Agents Chemother 1994;38:604-7.
5. Studies of Ocular Complications of AIDS Research Group, in collaboration with AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscamet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20.
6. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Bio-chem 1987;162:156-9.
7. Yerly S, Kaiser L, Baumberger C, Hirschel B, Perrin L. Early and prolonged decrease of viremia in HIV-1 infected patients treated with didanosine. J Acquir Immune Defic Syndr 1995;8:358-64.
8. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin L. Response of HIV RNA to didanosine as predictive marker of survival. AIDS 1995;9:159-63.
9. Jacobson MA, Wulfsohn M, Feinberg JE, et al. Phase II dose-ranging trial of foscamet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. AIDS 1994;8:451-9.
10. Jacobson MA, Kramer F, Bassiakos Y, et al. Randomized phase I trial of two different combination foscamet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. J Infect Dis 1994; 170:189-93.
11. Katzenstein DA, Winters M, Bubp J, Israelski D, Winger E, Merigan TC. Quantitation of human immunodeficiency vims by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. J Infect Dis 1994;169:416-9.
12. Katlama C, European Lamivudine HIV working group. Combination 3TC (lamivudine)/ZDV (zidovudine) vs. ZDV monotherapy in ZDV naive HIV-1 positive patients with CD4 of 100-400 cells/mm3. AIDS 1994; 8(suppl 4):S6.